TELMISARTAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Telmisartan, and when can generic versions of Telmisartan launch?
Telmisartan is a drug marketed by Alembic, Amneal Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd V, Hisun Pharm Hangzhou, Inventia, Jubilant Generics, Mankind Pharma, Micro Labs, Mylan, Prinston Inc, Sandoz, Torrent, Zydus Pharms, Lupin Ltd, Macleods Pharms Ltd, and Natco. and is included in thirty NDAs.
The generic ingredient in TELMISARTAN is hydrochlorothiazide; telmisartan. There are thirty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; telmisartan profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TELMISARTAN?
- What are the global sales for TELMISARTAN?
- What is Average Wholesale Price for TELMISARTAN?
Summary for TELMISARTAN
US Patents: | 0 |
Applicants: | 20 |
NDAs: | 30 |
Finished Product Suppliers / Packagers: | 26 |
Raw Ingredient (Bulk) Api Vendors: | 151 |
Clinical Trials: | 272 |
Patent Applications: | 4,625 |
Drug Prices: | Drug price information for TELMISARTAN |
Drug Sales Revenues: | Drug sales revenues for TELMISARTAN |
What excipients (inactive ingredients) are in TELMISARTAN? | TELMISARTAN excipients list |
DailyMed Link: | TELMISARTAN at DailyMed |
Recent Clinical Trials for TELMISARTAN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tyler J Curiel | Early Phase 1 |
THPharm Corp. | Phase 1 |
HK inno.N Corporation | Phase 1 |
Pharmacology for TELMISARTAN
Drug Class | Angiotensin 2 Receptor Blocker |
Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for TELMISARTAN
Paragraph IV (Patent) Challenges for TELMISARTAN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MICARDIS | Tablets | telmisartan | 20 mg, 40 mg and 80 mg | 020850 | 1 | 2006-12-26 |
US Patents and Regulatory Information for TELMISARTAN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma | TELMISARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; telmisartan | TABLET;ORAL | 208727-002 | Dec 15, 2016 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Prinston Inc | TELMISARTAN | telmisartan | TABLET;ORAL | 207882-002 | May 3, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Mankind Pharma | TELMISARTAN | telmisartan | TABLET;ORAL | 218157-002 | Oct 15, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Prinston Inc | TELMISARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; telmisartan | TABLET;ORAL | 209028-001 | Nov 6, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for TELMISARTAN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim International GmbH | Micardis | telmisartan | EMEA/H/C/000209 HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type-2 diabetes mellitus with documented target-organ damage. |
Authorised | no | no | no | 1998-12-16 | |
Krka, d.d., Novo mesto | Tolura | telmisartan | EMEA/H/C/001196 HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. |
Authorised | yes | no | no | 2010-06-04 | |
Teva B.V. | Telmisartan Teva Pharma | telmisartan | EMEA/H/C/002511 Treatment of essential hypertension in adults. |
Authorised | yes | no | no | 2011-10-03 | |
Teva B.V. | Telmisartan Teva | telmisartan | EMEA/H/C/001146 Treatment of essential hypertension in adults |
Withdrawn | yes | no | no | 2010-01-25 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
TELMISARTAN Market Analysis and Financial Projection Experimental
More… ↓